BridgeBio Pharma BBIO Research and Development Services — Contract with customer, liability
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
As of March 31, 2026 and December 31, 2025, there were $10.2 million and $5.0 million, respectively, of outstanding receivables relating to the Bayer License Agreement on our condensed consolidated balance sheets. During the three months ended March 31, 2026 and 2025, we recognized license and services revenue and royalty revenue of $10.3 million and $76.1 million, respectively, under the Bayer License Agreement. Our condensed consolidated balance sheet as of March 31, 2026 includes a deferred revenue balance of $2.7 million ($0.8 million presented as “Deferred revenue, current portion” and $1.9 million as “Deferred revenue, net of current portion”) related to our research and development services obligations. Our condensed consolidated balance sheet as of December 31, 2025, includes a deferred revenue balance of $2.9 million ($0.8 million presented as “Deferred revenue, current portion” and $2.1 million as “Deferred revenue, net of current portion”) related to our research and development services obligations.
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's research and development services — contract with customer, liability?
- BridgeBio Pharma (BBIO) reported research and development services — contract with customer, liability of $2.7M in Q1 2026.
- What does research and development services — contract with customer, liability mean?
- This represents the total financial obligation arising from contracts with customers for research and development services where the company has received consideration but has not yet fulfilled its performance obligations. It serves as a measure of the company's unearned service commitments. This liability is typically settled as the company performs the specified R&D activities over time.
Ask your AI about BridgeBio Pharma's research and development services — contract with customer, liability.
Connect your AI assistant and compare it to peers, right in your chat.
